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Essentials 
 The long-term effects of VKORC1 and CYP2C9 variants on clinical outcomes 
remains unclear. 
 We followed 774 patients ≥65 years with venous thromboembolism for a 
median duration of 30 months. 
 
 Patients with CYP2C9 variants are at increased risk of death and non-major 
bleeding. 
 Patients with genetic variants have a slightly lower anticoagulation quality 
only. 
 
Abstract 
Background 
The long-term effect of polymorphisms of the vitamin K-epoxide reductase 
(VKORC1) and the cytochrome P450 enzyme gene (CYP2C9) on clinical outcomes 
remains unclear.  
Objectives 
We examined the association between CYP2C9/VKORC1 variants and long-term 
clinical outcomes in a prospective cohort study of elderly patients treated with 
vitamin K antagonists for venous thromboembolism (VTE).  
Methods 
We followed 774 consecutive patients aged ≥65 years with acute VTE from nine 
Swiss hospitals for a median duration of 30 months. The median duration of initial 
anticoagulant treatment was 9.4 months. The primary outcome was the time to any 
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clinical event, i.e. the composite endpoint of overall mortality, major- and non-major 
bleeding, and recurrent VTE.  
Results 
Overall, 604 (78%) patients had a CYP2C9 or VKORC1 variant. Three hundred 
thirty-four patients (43.2%) had any clinical event, 119 (15.4%) died, 100 (12.9%) 
had major and 167 (21.6%) non-major bleeding, and 100 (12.9%) recurrent VTE. 
After adjustment, CYP2C9 (but not VKORC1) variants were associated with any 
clinical event (hazard ratio [HR] 1.34; 95% confidence interval [CI] 1.08-1.66), death 
(HR 1.74; 95% CI 1.19-2.52), and clinically relevant non-major bleeding (sub-hazard 
ratio [SHR] 1.39; 95% CI 1.02-1.89), but not with major bleeding (SHR 1.03; 95% CI: 
0.69-1.55) or recurrent VTE (SHR 0.95; 95% CI 0.62-1.44). Patients with genetic 
variants had a slightly lower anticoagulation quality.  
Conclusions 
CYP2C9 was associated with long-term overall mortality and non-major bleeding. 
While genetic variants were associated with a slightly lower anticoagulation quality, 
there was no relationship between genetic variants and major bleeding or VTE 
recurrence. 
 
 
Keywords 
Venous Thromboembolism; anticoagulants; phenprocoumon; cytochrome P-450 
CYP2C9; mortality 
 
Introduction 
Personalized medicine based on genetic factors is seen as a promising 
strategy to improve patient care and save healthcare costs, in particular with regard 
to anticoagulation treatment.[1-7] Despite the increasing use of direct oral 
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anticoagulants, vitamin K antagonists (VKAs) will continue to play a major role and 
improving the safety of anticoagulant treatment with VKAs remains an important 
goal.[8, 9] Main safety issues related to VKAs are bleeding as well as 
thromboembolic events, which both depend on the quality of anticoagulation.[10, 11] 
Achieving a stable anticoagulation control is difficult because of a large variability of 
VKA response across individuals.[12] A major part of this variability results from 
polymorphisms of the vitamin K-epoxide reductase (VKORC1) and the cytochrome 
P450 enzyme gene (CYP2C9), which both influence VKA metabolism.[13-22] 
Patients with a CYP2C9 genetic variant metabolize VKA to a lesser degree, resulting 
in higher levels of VKA metabolites and in decreased VKA dose requirements [6, 23]. 
VKORC1 encodes for Vitamin K-epoxide reductase subunit 1, which converts 
vitamin K into its active form [6]. Patients with the VKORC1 G1639A variant are 
more sensitive to VKA and dose requirements are lower as well [6]. 
To date, the clinical impact of measuring genetic polymorphisms in patients 
receiving VKAs still remains unclear.[4, 9, 24-27] Genetics-based dosing algorithms 
focusing on the initiation of anticoagulation did not demonstrate a clear benefit in 
terms of anticoagulation quality, as shown in several recent randomized-controlled 
trials.[24-27] In addition, a recent systematic review did not detect relevant 
differences in bleeding events between patients with and without VKORC1 variants, 
and only a slightly higher bleeding risk in patients with CYP2C9*3 variants.[22] 
However, these studies were limited by relatively small sample sizes and/or short 
follow-up periods, and methodologically more rigorous studies were requested.[22, 
27] Moreover, previous studies focused on the initiation of anticoagulation only and 
the long-term effects of genetic polymorphisms are unknown. To fill this gap of 
knowledge, we examined the association between CYP2C9 and VKORC1 variants 
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and long-term clinical outcomes in a prospective multicenter cohort study of elderly 
patients treated with VKA for venous thromboembolism (VTE).[28, 29] 
 
Methods 
Cohort sample 
The study was conducted between September 2009 and December 2013 as 
part of the SWIss venous Thromboembolism COhort (SWITCO65+), a prospective 
multicenter cohort study that assessed long-term medical outcomes and quality of 
life in elderly patients with acute VTE from all five university hospitals and four high-
volume non-university hospitals in Switzerland.[28, 29] Consecutive patients aged 65 
years or older with an acute, objectively confirmed VTE were identified in the 
inpatient and outpatient services of all participating study sites. Patients were 
excluded in case of inability to provide consent (e.g., severe dementia), thrombosis 
at different site than DVT or PE, impossible follow-up (e.g. terminal disease), or 
insufficient German or French language skills. For the sake of this analysis, we 
considered patients treated with VKAs only. A detailed description of the study 
methods was published elsewhere.[28, 29] The study was approved by the ethics 
committees at each participating site. 
 
Baseline data collection 
Trained study nurses prospectively collected baseline demographics (age, 
sex), VTE-related information (localization of the index VTE [PE, proximal/distal 
DVT], type of VTE [provoked, unprovoked, cancer-related], history of prior VTE, and 
family history of VTE), vital signs (heart rate, systolic blood pressure), body mass 
index, co-morbid conditions (recent immobilization, history of major bleeding, acute 
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rheumatic disease, inflammatory bowel disease, cerebrovascular disease, chronic 
renal and pulmonary disease), laboratory findings (hemoglobin, creatinine), 
concomitant antiplatelet and non-steroidal anti-inflammatory therapy, polypharmacy, 
and VTE-related treatments (type and duration of initial parenteral anticoagulation 
and duration of VKA therapy) from all enrolled patients using standardized data 
collection forms. 
 
Genetic analyses 
A specifically designed haemostasis biobank was implemented before 
inclusion of patients.[29] At the day of enrollment, one EDTA-whole blood sample 
(2.7ml, Sarstedt, Nümbrecht, Germany) was collected. After plasma removal by 
centrifugation, blood cells were stored at -80°C until DNA extraction (Qiacube 
automated extraction plus Qiagen DNA blood mini kit, Qiagen, Hombrechtikon, 
Switzerland). Allelic identifications of VKORC1 and CYP2C9 were made by melting 
curve analysis of fluorescent Q-PCR amplification products. “LightMix for the 
detection of human VKORC1 G1639A” and “LightMix for the detection of human 
CYP2C9*2 and CYP2C9*3” kits (TIBMOLBIOL, Berlin, Germany), containing primers 
and probes, were used. PCR reactions were performed as advised by the 
manufacturer on a LightCycler 1.8 (Roche Diagnostics, Rotkreuz, Switzerland). 
Patients and managing physicians were blinded to the results of these analyses. 
 
Study outcomes 
The primary outcome was the time to any clinical event, i.e. a composite 
outcome of death, major bleeding, clinically relevant non-major bleeding, or recurrent 
VTE. Major bleeding was defined as fatal bleeding, symptomatic bleeding in a critical 
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organ (intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, pericardial, 
or intramuscular with compartment syndrome), bleeding with a reduction in 
hemoglobin ≥20 g/l, or bleeding leading to a transfusion ≥2 units of packed red blood 
cells. [30] Clinically relevant non-major bleeding was defined as bleeding that did not 
meet the definition of major bleeding but required medical attention (i.e., a physician 
contact). Recurrent VTE was defined as objectively confirmed, new or recurrent 
proximal or distal DVT or PE, as previously described.[28, 29]  
The secondary outcomes were the individual outcomes of overall mortality, 
major bleeding, clinically relevant non-major bleeding, and recurrent VTE. Additional 
outcomes were the percentage of time within the therapeutic INR range (TTR; 2.0-
3.0),[31] the percentage of time above the therapeutic INR range (>3.0), the time to 
a therapeutic INR (defined as three consecutive INR measurements in the range 
between 2.0 and 3.0), and the time to first INR above 4.5. 
During follow-up, patients were contacted semi-annually, alternating between 
face-to-face evaluations and telephone calls. Detailed information regarding the 
date, type and circumstance of outcomes were collected from the patient, and/or the 
patient’s family members, primary care physician and medical chart. We also 
recorded all INR values measured by the family physician during the follow-up 
period. 
All outcomes were reviewed and adjudicated by an independent committee of 
three blinded clinical experts. Based on the full consensus of this committee, deaths 
were classified as definitely due to PE (e.g., confirmed by autopsy or following 
severe PE), possibly due to PE (e.g., sudden death without obvious cause), due to 
major bleeding and due to other causes. Bleeding-related death was defined as 
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death following intracranial hemorrhage or hemodynamic deterioration due to major 
bleeding.[32] 
 
Statistical analyses 
We present Kaplan-Meier curves for any clinical event and mortality, as well 
as cumulative incidence curves adjusted for the competing risk of death for major 
bleeding, clinically relevant non-major bleeding, and recurrent VTE [33]. We 
examined the association between CYP2C9 and VKORC1 variants and any clinical 
outcome event and death using Cox regression using robust standard errors, 
adjusting for previously published predictors of the respective outcome as well as 
periods of anticoagulation as a time-varying covariate.[34-36] 
We examined associations between CYP2C9 and VKORC1 variants and the 
time to a first VTE recurrence, major bleeding, and clinically relevant non-major 
bleeding using competing risk regression according to Fine and Gray,[37] accounting 
for non-PE- or non-bleeding-related death as a competing event. We adjusted the 
models for previously published predictors of bleeding and VTE recurrence.[34, 38-
54] As we aimed to predict overall adverse events, we considered the full 
observation period from diagnosis until the end of follow-up, adjusting for periods of 
anticoagulation as a time-varying covariate. 
We calculated the percentage of time spent within one of three specified INR 
ranges (<2.0, 2.0-3.0, >3.0) using the Rosendaal method [31] and compared groups 
using linear regression. We examined the association between CYP2C9 and 
VKORC1 variants and the time to the first therapeutic INR and the time to the first 
INR >4.5 using Cox-regression with robust standard errors. Only the initial VKA 
treatment was considered. Time was censored at stop of initial treatment, death, or 
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withdrawal/loss of follow-up. Analyses were adjusted for known influencing factors of 
anticoagulation quality, including age, sex, provoked VTE, active cancer, diabetes, 
heart failure, chronic pulmonary disease, chronic liver disease, renal failure (GFR 
<30 ml/min.), body mass index, hypertension, and smoking status.[55-57] All 
analyses were done using Stata 13 (Stata Corporation, College Station, Texas). 
 
Results 
Patient characteristics 
Of 1863 patients screened, 1003 were included in the study cohort and 744 
were analyzed for the purpose of this study (Figure 1). Analyzed patients did not 
differ from non-analyzed patients in terms of age (median age 75 vs. 74 years) and 
sex (women 46% vs. 50%). 
Overall, 78% of patients (n=604) had a CYP2C9 or VKORC1 variant. 
CYP2C9*2 polymorphisms were found in 26% of patients (n=200), CYP2C9*3 in 
12% (n=95), VKORC1 in 66% (n=510), and both CYP29C and VKORC1 variants in 
24% (n=187). Patient baseline characteristics did not differ in patients with and 
without a genetic variant (Table 1). Although patients with a genetic variant had a 
shorter initial parenteral anticoagulation duration than patients without variant (9 vs. 
12 days), the duration of the initial anticoagulation with vitamin K antagonists was 
comparable (9.7 vs. 8.4 months) (Table 1). 
 
Clinical outcomes 
The median observation time was 30 months (interquartile range 24 to 41 
months). The primary outcome, the composite endpoint of death, major or non-major 
clinically relevant bleeding, or VTE recurrence, occurred in 43% of patients (n=334). 
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Overall, 15% of patients died (n=119), 13% (n=100) had major bleeding, 22% 
(n=167) clinically relevant non-major bleeding, and 13% (n=100) recurrent VTE. 
While patients with a CYP2C9 variant had a higher cumulative 3-year 
incidence of any clinical outcome event than those without these variants (52.3% vs. 
41.1%; Figure 2), the cumulative incidence did not differ much in patients with or 
without VKORC1 variants (47.1% vs. 41.8%). Patients with a CYP2C9 variant had a 
higher cumulative 3-year incidence of death and clinically relevant non-major 
bleeding but not major bleeding or recurrent VTE (Figure 3). 
After adjustment, CYP2C9 variants were associated with any clinical outcome 
event (hazard ratio [HR] 1.34; 95% confidence interval [CI] 1.08, 1.66), death (HR 
1.74; 95% CI 1.19, 2.52), and clinically relevant non-major bleeding (sub-hazard ratio 
[SHR] 1.39; 95% CI 1.02, 1.89), but not with major bleeding (SHR 1.03; 95% CI 0.69, 
1.55) or recurrent VTE (SHR 0.95; 95% CI 0.62, 1.44) (Table 2). Patients with both 
CYP2C9 and VKORC1 variants had a higher risk of any clinical event (HR 1.40; 95% 
CI 1.11, 1.77) and clinically relevant non-major bleeding (SHR 1.78; 95% CI 1.30, 
2.44). 
 
Quality of anticoagulation 
Associations between CYP2C9 and VKORC1 variants and measures of 
anticoagulation quality are shown in Table 3. Compared to patients without CYP2C9 
variants, patients with a CYP2C9 variant spent less time in the therapeutic INR 
range (adjusted difference -3.7%; 95% CI -7.0, -0.4). Similarly, patients with CYP2C9 
variants spent more time with an INR above the therapeutic range (adjusted 
difference 3.3; 95% CI 0.8, 5.7), were less likely to achieve a therapeutic INR 
(adjusted HR 0.81; 95% CI 0.68, 0.96), and more likely to have an INR >4.5 
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(adjusted HR 1.42; 95% CI 1.11, 1.81). Patients with a VKORC1 variant were more 
likely to have an INR >4.5 (adjusted HR 1.43; 95% CI 1.10, 1.85). 
 
Discussion 
Our results demonstrated a association between CYP2C9 genetic variants 
and the composite endpoint of death, major bleeding, clinically relevant non-major 
bleeding, and recurrent VTE. This result was driven by a 74% higher mortality and a 
39% higher risk of clinically relevant non-major bleeding in patients with CYP2C9 
variants. While patients with genetic variants, in particular CYP2C9, had a slightly 
lower anticoagulation quality, we found no relationship between genetic variants and 
major bleeding or recurrent VTE. 
To our knowledge, our work is the first study to demonstrate a association 
between CYP2C9 variants and mortality. Interestingly, the increased mortality does 
not appear to be driven by a higher rate of major bleeding or recurrent VTE. Several 
explanations for the higher mortality rate in patients with CYP2C9 are possible. First, 
genetic variants may affect mortality based on mechanisms not related to 
anticoagulation quality. A small observational study demonstrated a higher risk of 
stroke and myocardial infarction in patients with VKORC1 variants, the underlying 
mechanism for the increased risk of cardiovascular complications remaining 
unexplained.[58] Second, although we adjusted for many co-variates, we cannot fully 
exclude the possibility that the higher mortality in patients with CYP2C9 variants is 
caused by residual confounding. 
We did not observe an increased risk of major bleeding in patients with 
CYP2C9 or VKORC1 variants. This finding is consistent with previous studies 
focusing on short-term clinical outcomes. In a systematic review by Jorgensen et al., 
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which pooled data from several smaller-sized observational studies, no association 
between genetic variants and major bleeding was reported.[22] Similarly, in a sub-
study of the ENGAGE AF-TIMI 48 phase III clinical trial (edoxaban for stroke 
prophylaxis in patients with atrial fibrillation), no association between 
CYP2C9/VKORC1 variants and major bleeding was found.[59] However, as 
demonstrated in several smaller observational studies,[60-62] we observed a 
association between CYP2C9 variants and clinically relevant non-major bleeding 
(adjusted SHR 1.39; 95% CI 1.02, 1.89). 
We did not find an association between genetic variants and recurrent VTE. 
This result is consistent with the findings of a small retrospective study conducted in 
120 patients with mechanical heart valves, which did not report an increased risk of 
VTE in patients with genetic variants.[58] 
In our cohort, genetic variants, in particular CYP2C9, were associated with a 
lower anticoagulation quality, but the absolute differences in anticoagulation quality 
measures were small. Even though prior studies have shown a consistent 
association between genetic variants and VKA dose requirements,[14, 61, 63-69] the 
evidence with regard to anticoagulation quality is much more limited. In a systematic 
review, the magnitude of associations between CYP2C9 and VKORC1 genetic 
variants and different measures of anticoagulation quality was moderate at best.[22] 
Randomized-controlled trials comparing genetic-based dosing schedules for initiation 
of anticoagulation to standard care did not demonstrate a relevant benefit in terms of 
quality of anticoagulation or clinical outcomes.[24-27] Overall, the results from our 
cohort of elderly patients indicate that although patients with genetic variants appear 
to have a somewhat lower anticoagulation quality and a higher risk of non-major 
bleeding (CYP2C9), but they do not have an increased risk of major bleeding. Thus, 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
the costly measurement of CYP2C9 and VKORC1 variants is unlikely to have a 
relevant beneficial effect on anticoagulation quality and clinical outcomes of elderly 
patients with VTE. Interestingly, associations between genetic variants and 
anticoagulation quality as well as clinical outcomes were much more prominent in 
case of CYP2C9. This observation suggests that fluctuations in VKA concentrations 
are more important than VKA sensitivity.  
Our study has several strengths. In contrast to prior studies, our study had a 
long-term follow-up, larger sample size, and clinically relevant outcome variables. 
[14, 22, 24-27, 59-69] In addition, we focused on elderly patients, a population at risk 
for both bleeding complications and death.[70] The fact that we enrolled patients 
from university and non-university hospitals increases the generalizability of our 
findings. Because patients and managing physicians were blinded to the results of 
the genetic analyses, a performance bias is unlikely. 
Our study has several potential limitations. First, our study included patients 
aged 65 years or older only. Thus, the results may not be generalizable to younger 
patients. Second, our study included exclusively patients with VTE and therefore, our 
results may not be generalizable to other populations, such as patients with atrial 
fibrillation. Finally, even though we adjusted our analyses for many covariates, we 
might have missed important predictor variables. 
In conclusion, we found a association between CYP2C9 genetic variants and 
long-term clinical outcomes, notably overall mortality and clinically relevant non-
major bleeding. In contrast, we found no relationship between VKORC1 variants and 
clinical outcomes. While genetic variants, in particular CYP2C9, appear to be 
associated with a somewhat lower anticoagulation quality, there was no relationship 
between genetic variants and major bleeding or recurrent VTE. 
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Figure Legends 
 
Figure 1. Patient flow chart. *Multiple reasons may apply. 
 
Figure 2. Kaplan-Meier estimates of a first clinical event (death, major or clinically 
relevant non-major bleeding, or VTE recurrence) according to presence of CYP2C9 
or VKORC1 variants. The cumulative 3-year incidence of a first clinical event was 
52.3% for patients with a CYP2C9 variant vs. 41.1% for patients without variant and 
47.1% for patients with a VKORC1 variant vs. 41.8% for patients without variant. 
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Figure 3. Cumulative incidences of (A) death, (B) major bleeding, (C) clinically 
relevant non-major bleeding, and (D) VTE recurrences according to the presence of 
CYP2C9 or VKORC1 variants. Compared to patients without variant, patients with a 
CYP2C9 variant had a higher cumulative 3-year incidence of death (20.4% vs. 
12.4%) and non-major clinically relevant bleeding (27.5% vs. 21.3%). Graphs were 
adjusted for the competing risk of death if appropriate. 
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Table 1.  Baseline characteristics by presence of any genetic variant 
 All 
(N=774) 
Any genetic variant* 
(N=604) 
No genetic variant 
(N=170) 
Missing values 
  n (%) or median (IQR) n (%) 
Age, years 75.0 (69.0; 81.0)  75.0 (69.0; 81.0)  74.5 (69.0; 81.0) 0 (0) 
Female sex 355 (46)      280 (46)           75 (44)     0 (0) 
BMI, kg/m
2
 26.8 (24.3; 29.9)  26.8 (24.3; 29.8)  26.9 (24.3; 30.6) 4 (1) 
Smoking status    2 (1) 
 current smoker 58 (8)       47 (8)           11 (6)      
 past smoker 315 (41)      248 (41)           67 (39)      
 never smoker 399 (52)      307 (51)           92 (54)      
Localization of thrombosis                                        0 (0) 
  distal DVT only 53 (7)       44 (7)            9 (5)      
  proximal DVT 165 (21)      127 (21)           38 (22)      
  PE 556 (72)      433 (72)          123 (72)      
Prior VTE 229 (30)      181 (30)           48 (28)     0 (0) 
Family history of PE/DVT 140 (18)      112 (19)           28 (16)     7 (1) 
Provoked index VTE 214 (28)      171 (28)           43 (25)     0 (0) 
Active cancer
†
 82 (11)       60 (10)           22 (13)     0 (0) 
Arterial hypertension 500 (65)      392 (65)          108 (64)     0 (0) 
Diabetes mellitus 120 (16)       89 (15)           31 (18)     0 (0) 
Chronic heart failure 91 (12)       72 (12)           19 (11)     0 (0) 
Acute rheumatic disease during the last 3 
months 
25 (3)       21 (3)            4 (2)     0 (0) 
Inflammatory bowel disease 27 (3)       19 (3)            8 (5)     0 (0) 
History of major bleeding
‡
 72 (9)       52 (9)           20 (12)     1 (0) 
Cerebrovascular disease (stroke, TIA) 72 (9)       59 (10)           13 (8)     0 (0) 
Chronic renal disease 142 (18)      113 (19)           29 (17)     0 (0) 
Chronic pulmonary disease 104 (13)       87 (14)           17 (10)     0 (0) 
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Chronic liver disease 11 (1)        9 (1)            2 (1)     0 (0) 
Anemia
§
 267 (37)      214 (38)           53 (34)     49 (6) 
Creatinine >107 µmol/L 185 (26)      146 (26)           39 (26)     63 (8) 
Systolic BP <100 mm Hg 27 (4)       20 (3)            7 (4)     13 (2) 
Heart rate ≥110/min. 73 (10)      214 (38)           53 (34)     15 (2) 
Immobilization during the last 3 months 154 (20)      122 (20)           32 (19)     0 (0) 
Antiplatelet therapy 254 (33)      189 (31)           65 (38)     0 (0) 
NSAID 72 (9)       62 (10)           10 (6)     0 (0) 
Polypharmacy
¶
 388 (50)      309 (51)           79 (46)     0 (0) 
Duration of initial parenteral AC, days 9.0 (6.0; 16.0)   9.0 (6.0; 14.0) 12.0 (7.0; 19.0) 0 (0) 
Duration of initial VKA therapy, months 9.4 (5.3; 29.1)   9.7 (5.2; 29.0)   8.4 (5.4; 29.2) 0 (0) 
 
Abbreviations: IQR= interquartile range, BMI=body mass index, DVT= deep vein thrombosis; PE= pulmonary embolism; VTE= venous thromboembolism; TIA= 
transient ischemic attack; BP= blood pressure; NSAID= nonsteroidal anti-inflammatory drug; AC= anticoagulation; VKA= vitamin K antagonist 
* CYP2C9*2, CYP2C9*3, or VKORC1 G1639A genetic variant 
† 
Solid or hematologic cancer requiring chemotherapy, radiotherapy, surgery, and/or palliative care during the last 3 months 
‡ 
Bleeding that led to a hospital stay or transfusions 
§ 
Serum hemoglobin <130 g/L for men or <120 g/L for women 
¶ 
Pharmacotherapy with >4 different drugs
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Table 2.  Associations between CYP2C9 and VKORC1 variants and clinical outcomes 
Clinical outcome /  
genetic variant (s) 
No. of events/ patients 
(%) 
No. of events/ patients 
(%) 
Unadjusted HR or SHR (95%-CI) Adjusted HR or SHR (95%-CI)
§
 
 With variant(s) Without variant(s)   
Any clinical event (Death, VTE recurrence, major bleeding, or clinically relevant non-major bleeding) 
CYP2C9 variant
† 
138/ 281 (49.1) 196/ 493 (39.8) 1.29 (1.04, 1.60) 1.34 (1.08, 1.66) 
VKORC1 variant
‡ 
228/ 510 (44.7) 106/ 264 (40.2) 1.16 (0.92, 1.46) 1.12 (0.88, 1.41) 
CYP2C9 and VKORC1 variants  99/ 187 (52.9) 235/ 587 (40.0) 1.44 (1.14, 1.81) 1.40 (1.11, 1.77) 
Death     
CYP2C9 variant
†
 55/ 281 (19.6) 64/ 493 (13.0) 1.55 (1.08, 2.22) 1.74 (1.19, 2.52) 
VKORC1 variant
‡
 76/ 510 (14.9) 43/ 264 (16.3) 0.90 (0.62, 1.31) 0.82 (0.55, 1.22) 
CYP2C9 and VKORC1 variants  34/ 187 (18.2) 85/ 587 (14.5) 1.25 (0.84, 1.86) 1.29 (0.84, 1.96) 
Major bleeding     
CYP2C9 variant
†
 37/ 281 (13.2) 63/ 493 (12.8) 1.03 (0.69, 1.54) 1.03 (0.69, 1.55) 
VKORC1 variant
‡
 64/ 510 (12.5) 36/ 264 (13.6) 0.92 (0.61, 1.38) 0.93 (0.61, 1.40) 
CYP2C9 and VKORC1 variants  23/ 187 (12.3) 77/ 587 (13.1) 0.93 (0.58, 1.48) 0.91 (0.57, 1.46) 
Clinically relevant non-major bleeding   
CYP2C9 variant
†
 72/ 281 (25.6) 95/ 493 (19.3) 1.38 (1.01, 1.87) 1.39 (1.02, 1.89) 
VKORC1 variant
‡
 119/ 510 (23.3) 48/ 264 (18.2) 1.32 (0.95, 1.85) 1.32 (0.94, 1.85) 
CYP2C9 and VKORC1 variants  58/ 187 (31.0) 109/ 587 (18.6) 1.81 (1.32, 2.50) 1.78 (1.30, 2.44) 
VTE recurrence     
CYP2C9 variant
†
 35/ 281 (12.5) 65/ 493 (13.2) 0.93 (0.62, 1.40) 0.95 (0.62, 1.44) 
VKORC1 variant
‡
 66/ 510 (12.9) 34/ 264 (12.9) 1.00 (0.66, 1.51) 1.11 (0.72, 1.70) 
CYP2C9 and VKORC1 variants  25/ 187 (13.4) 75/ 587 (12.8) 1.03 (0.65, 1.62) 1.15 (0.72, 1.84) 
 
Abbreviations: HR= hazard ratio; CI= confidence interval; SHR= sub-hazard ratio 
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*
 Death, VTE recurrence, major bleeding, or clinically relevant non-major bleeding 
†
 CYP2C9*2 and CYP2C9*3 genetic variants 
‡
 VKORC1 G1639A genetic variant 
§
 Adjusted for age, sex, active cancer, provoked VTE, prior VTE, heart failure, chronic pulmonary disease, overt PE, history of major bleeding, heart rate 
≥110/min, systolic BP <100 mm Hg, anemia, creatinine >107 µmol/L, antiplatelet treatment, and periods of anticoagulation as time-varying covariate 
¶
 Adjusted for age, sex, active cancer, immobilization, heart failure, chronic pulmonary disease, overt PE, history of major bleeding, heart rate ≥110/min, systolic 
BP <100 mm Hg, anemia, creatinine >107 µmol/L, and periods of anticoagulation as a time-varying covariate 
**
 Adjusted for age, sex, active cancer, history of major bleeding, overt PE, anemia, creatinine >107 µmol/L, antiplatelet treatment, and periods of anticoagulation 
as time-varying covariate 
††
 Adjusted for age, sex, active cancer, provoked VTE, prior VTE, and periods of anticoagulation as time-varying covariate
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Table 3.  Associations between CYP2C9 and VKORC1 variants and quality of anticoagulation 
 
Genetic variants Percentage of time in the therapeutic 
INR range (2.0-3.0) 
Percentage of time above therapeutic INR range
 
(>3.0) 
Time to a first 
therapeutic INR (≥2.0) 
Time to first INR >4.5 
 Mean (SD) Adjusted difference  
(95% CI) 
‡
 
Mean (SD) Adjusted difference  
(95% CI) 
‡
 
Adjusted hazard ratio  
(95%-CI) 
‡
 
Adjusted hazard ratio  
(95%-CI) 
‡
 
CYP2C9 variant* 
No (n=481) 
Yes (n=274) 
 
61.1 (22.8) 
57.4 (23.7) 
 
 
-3.7 (-7.0, -0.4) 
 
13.8 (15.3) 
17.1 (18.7) 
 
 
3.3 (0.8, 5.7) 
 
1 (reference) 
0.81 (0.68, 0.96) 
 
1 (reference) 
1.42 (1.11, 1.81) 
VKORC1 variant
† 
No (n=257) 
Yes (n=498) 
 
58.4 (23.7) 
60.4 (22.9) 
 
 
2.4 (-1.0, 5.7) 
 
13.5 (15.6) 
15.8 (17.1) 
 
 
2.3 (-0.2, 4.8) 
 
1 (reference) 
1.01 (0.85, 1.20) 
 
1 (reference) 
1.43 (1.10, 1.85) 
CYP2C9 and 
VKORC1 variant 
No (n=571) 
Yes (n=184) 
 
 
60.2 (23.2) 
58.3 (23.4) 
 
 
 
-1.5 (-5.2, 2.2) 
 
 
13.9 (15.4) 
18.4 (19.7) 
 
 
 
4.4 (1.7, 7.2) 
 
 
1 (reference) 
0.80 (0.65, 0.97) 
 
 
1 (reference) 
1.47 (1.13, 1.93) 
 
Abbreviations: INR= international normalized ratio; CI= confidence interval 
*
 CYP2C9*2 and CYP2C9*3 genetic variants 
† VKORC1 G1639A genetic variant 
‡
 Adjusted for age, sex, provoked VTE, active cancer, diabetes, heart failure, chronic pulmonary disease, chronic liver disease, severe renal failure (GFR <30 
ml/min.), body mass index, hypertension, and smoking status 
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